{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:15:04Z","timestamp":1791926104630,"version":"4.3.4"},"reference-count":61,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,3]],"date-time":"2018-05-03T00:00:00Z","timestamp":1525305600000},"content-version":"vor","delay-in-days":367,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.ymthe.2017.03.023","type":"journal-article","created":{"date-parts":[[2017,3,31]],"date-time":"2017-03-31T07:31:35Z","timestamp":1490945495000},"page":"1069-1075","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":588,"title":["FDA-Approved Oligonucleotide Therapies in 2017"],"prefix":"10.1016","volume":"25","author":[{"given":"Cy A.","family":"Stein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Castanotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2017.03.023_bib1","first-page":"467","article-title":"A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS","volume":"133","year":"2002","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.ymthe.2017.03.023_bib2","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1126\/science.2200121","article-title":"Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase","volume":"249","author":"Tuerk","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2017.03.023_bib3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S1367-5931(97)80103-2","article-title":"The joys of in\u00a0vitro selection: chemically dressing oligonucleotides to satiate protein targets","volume":"1","author":"Eaton","year":"1997","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ymthe.2017.03.023_bib4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrd1955","article-title":"Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease","volume":"5","author":"Ng","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2017.03.023_bib5","doi-asserted-by":"crossref","first-page":"20556","DOI":"10.1074\/jbc.273.32.20556","article-title":"2\u2032-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain","volume":"273","author":"Ruckman","year":"1998","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2017.03.023_bib6","doi-asserted-by":"crossref","first-page":"10450","DOI":"10.1021\/bi00200a028","article-title":"Inhibition of receptor binding by high-affinity RNA ligands to vascular endothelial growth factor","volume":"33","author":"Jellinek","year":"1994","journal-title":"Biochemistry"},{"key":"10.1016\/j.ymthe.2017.03.023_bib7","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas","year":"2004","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2017.03.023_bib8","first-page":"2309","article-title":"VEGF inhibition study in ocular neovascularization (VISION): Second year efficacy data","volume":"46","author":"D\u2019Amico","year":"2005","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymthe.2017.03.023_bib9","unstructured":"http:\/\/ophthalmologytimes.modernmedicine.com\/ophthalmologytimes\/news\/modernmedicine\/modern-medicine-news\/valeant-acquires-eyetech."},{"key":"10.1016\/j.ymthe.2017.03.023_bib10","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2017.03.023_bib11","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.atherosclerosis.2015.06.011","article-title":"Screening and treatment of familial hypercholesterolemia - Lessons from the past and opportunities for the future (based on the Anitschkow Lecture 2014)","volume":"241","author":"Besseling","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ymthe.2017.03.023_bib12","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1194\/jlr.M400492-JLR200","article-title":"An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis","volume":"46","author":"Crooke","year":"2005","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.ymthe.2017.03.023_bib13","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1021\/ar00057a002","article-title":"Antisense oligonucleotides","volume":"28","author":"De Mesmaeker","year":"1995","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ymthe.2017.03.023_bib14","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1146\/annurev.nutr.20.1.169","article-title":"APOLIPOPROTEIN B: mRNA editing, lipoprotein assembly, and presecretory degradation","volume":"20","author":"Davidson","year":"2000","journal-title":"Annu. Rev. Nutr."},{"key":"10.1016\/j.ymthe.2017.03.023_bib15","unstructured":"Mahley, R. Biochemistry and Physiology of Lipid and Lipoprotein Metabolism. In Principles and Practice of Endocrinology and Metabolism, Third Edition, K.L. Becker, ed. (Lippincott Williams and Wilkins)."},{"key":"10.1016\/j.ymthe.2017.03.023_bib16","doi-asserted-by":"crossref","first-page":"e49006","DOI":"10.1371\/journal.pone.0049006","article-title":"Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy","volume":"7","author":"McGowan","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2017.03.023_bib17","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1161\/CIRCULATIONAHA.112.104125","article-title":"Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease","volume":"126","author":"Stein","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2017.03.023_bib18","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.jacc.2013.07.081","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Thomas","year":"2013","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.ymthe.2017.03.023_bib19","doi-asserted-by":"crossref","unstructured":"Excerpted from: Stein, C.A. (2016). Eteplirsen approved for Duchenne muscular dystrophy: The FDA faces a difficult choice. Mol. Ther. 24, 1884\u20131885.","DOI":"10.1038\/mt.2016.188"},{"key":"10.1016\/j.ymthe.2017.03.023_bib20","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s00439-016-1725-z","article-title":"Gene therapies that restore dystrophin expression for the treatment of Duchenne muscular dystrophy","volume":"135","author":"Robinson-Hamm","year":"2016","journal-title":"Hum. Genet."},{"key":"10.1016\/j.ymthe.2017.03.023_bib21","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ana.23982","article-title":"Eteplirsen for the treatment of Duchenne muscular dystrophy","volume":"74","author":"Mendell","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2017.03.023_bib22","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1016\/j.ddstr.2013.04.001","article-title":"Antisense oligonucleotides as personalized medicine for Duchenne muscular dystrophy","volume":"10","author":"van Deutekom","year":"2013","journal-title":"Drug Discov. Today Ther. Strateg."},{"key":"10.1016\/j.ymthe.2017.03.023_bib23","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(11)60756-3","article-title":"Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study","volume":"378","author":"Cirak","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2017.03.023_bib24","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ana.24555","article-title":"Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy","volume":"79","author":"Mendell","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2017.03.023_bib25","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S1474-4422(09)70211-X","article-title":"Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study","volume":"8","author":"Kinali","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymthe.2017.03.023_bib26","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1089\/hum.2014.086","article-title":"Translational and regulatory challenges for exon skipping therapies","volume":"25","author":"Aartsma-Rus","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2017.03.023_bib27","unstructured":"Carrol. J. UPDATED: The FDA decides that it can\u2019t decide yet on Sarepta\u2019s eteplirsen. http:\/\/www.fiercebiotech.com\/fda-decides-it-can-t-decide-yet-sarepta-s-eteplirsen."},{"key":"10.1016\/j.ymthe.2017.03.023_bib28","unstructured":"Feuerstein, A. Sarepta, FDA compromise on plan to secure Duchenne drug approval.\u00a0The Street, June 7, 2016. https:\/\/www.thestreet.com\/story\/13598536\/1\/sarepta-fda-compromise-on-plan-to-secure-duchenne-drug-approval.html."},{"key":"10.1016\/j.ymthe.2017.03.023_bib29","unstructured":"Editorial. Where\u2019s the drug, FDA? The Wall Street Journal, July 5, 2016. http:\/\/www.wsj.com\/articles\/wheres-the-drug-fda-1467413266."},{"key":"10.1016\/j.ymthe.2017.03.023_bib30","unstructured":"Harper, M. Approving a muscular dystrophy drug ignites a civil war at the FDA. Forbes, September 20, 2016. https:\/\/www.forbes.com\/sites\/matthewherper\/2016\/09\/20\/approving-a-muscular-dystrophy-drug-ignites-civil-war-at-the-fda\/."},{"key":"10.1016\/j.ymthe.2017.03.023_bib31","doi-asserted-by":"crossref","unstructured":"Excerpted from: Stein, C., Castanotto, D., Krishnan, A., and Nikolaenko, L. (2016). Defibrotide (Defitelio): A new addition to the stockpile of Food and Drug Administration-approved oligonucleotide drugs. Mol. Ther. Nucleic Acids 5, e346.","DOI":"10.1038\/mtna.2016.42"},{"key":"10.1016\/j.ymthe.2017.03.023_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vph.2013.05.001","article-title":"Defibrotide: properties and clinical use of an old\/new drug","volume":"59","author":"Pescador","year":"2013","journal-title":"Vascul. Pharmacol."},{"key":"10.1016\/j.ymthe.2017.03.023_bib33","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1182\/blood-2008-04-149682","article-title":"Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease","volume":"112","author":"Benimetskaya","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.03.023_bib34","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.clinre.2016.01.006","article-title":"Sinusoidal obstruction syndrome","volume":"40","author":"Valla","year":"2016","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"10.1016\/j.ymthe.2017.03.023_bib35","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.bbmt.2015.09.024","article-title":"Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment","volume":"22","author":"Dalle","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.ymthe.2017.03.023_bib36","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jceh.2014.10.002","article-title":"Sinusoidal obstruction syndrome (hepatic veno-occlusive disease)","volume":"4","author":"Fan","year":"2014","journal-title":"J.\u00a0Clin. Exp. Hepatol."},{"key":"10.1016\/j.ymthe.2017.03.023_bib37","doi-asserted-by":"crossref","first-page":"G1045","DOI":"10.1152\/ajpgi.00526.2002","article-title":"Embolization by sinusoidal lining cells obstructs the microcirculation in rat sinusoidal obstruction syndrome","volume":"284","author":"DeLeve","year":"2003","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.ymthe.2017.03.023_bib38","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-2002-23204","article-title":"Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease)","volume":"22","author":"DeLeve","year":"2002","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.ymthe.2017.03.023_bib39","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/bjh.12558","article-title":"BCSH\/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation","volume":"163","author":"Dignan","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ymthe.2017.03.023_bib40","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/bmt.2015.52","article-title":"Sinusoidal obstruction syndrome\/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT)","volume":"50","author":"Mohty","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.ymthe.2017.03.023_bib41","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1182\/blood-2015-10-676924","article-title":"Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure","volume":"127","author":"Richardson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.03.023_bib42","first-page":"CD009311","article-title":"Interventions for prophylaxis of hepatic veno-occlusive disease in people undergoing haematopoietic stem cell transplantation","volume":"5","author":"Cheuk","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ymthe.2017.03.023_bib43","doi-asserted-by":"crossref","first-page":"C371","DOI":"10.1152\/ajpcell.00193.2002","article-title":"Fibroblast growth factor 2 promotes microvessel formation from mouse embryonic aorta","volume":"284","author":"Akimoto","year":"2003","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.ymthe.2017.03.023_bib44","first-page":"26","article-title":"Biological roles of fibroblast growth factor-2","volume":"18","author":"Bikfalvi","year":"1997","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.ymthe.2017.03.023_bib45","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0065-230X(08)60305-X","article-title":"The FGF family of growth factors and oncogenes","volume":"59","author":"Basilico","year":"1992","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.ymthe.2017.03.023_bib46","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1083\/jcb.141.7.1659","article-title":"Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis","volume":"141","author":"Seghezzi","year":"1998","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.ymthe.2017.03.023_bib47","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1074\/mcp.R400008-MCP200","article-title":"Polyanions and the proteome","volume":"3","author":"Jones","year":"2004","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.ymthe.2017.03.023_bib48","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1021\/bi00430a047","article-title":"Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules","volume":"28","author":"Bashkin","year":"1989","journal-title":"Biochemistry"},{"key":"10.1016\/j.ymthe.2017.03.023_bib49","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1073\/pnas.84.8.2292","article-title":"Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix","volume":"84","author":"Vlodavsky","year":"1987","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2017.03.023_bib50","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/0006-291X(87)90292-0","article-title":"Fibroblast growth factors are present in the extracellular matrix produced by endothelial cells in\u00a0vitro: implications for a role of heparinase-like enzymes in the neovascular response","volume":"142","author":"Baird","year":"1987","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ymthe.2017.03.023_bib51","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1677\/erc.0.0070165","article-title":"Fibroblast growth factors, their receptors and signaling","volume":"7","author":"Powers","year":"2000","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.ymthe.2017.03.023_bib52","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1182\/blood-2015-10-676114","article-title":"What is going on between defibrotide and endothelial cells? Snapshots reveal the hot spots of their romance","volume":"127","author":"Palomo","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.03.023_bib53","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0014-2999(93)90864-E","article-title":"Defibrotide, a single-stranded polydeoxyribonucleotide acting as an adenosine receptor agonist","volume":"238","author":"Bianchi","year":"1993","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ymthe.2017.03.023_bib54","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1161\/ATVBAHA.111.240291","article-title":"Defibrotide interferes with several steps of the coagulation-inflammation cycle and exhibits therapeutic potential to treat severe malaria","volume":"32","author":"Francischetti","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ymthe.2017.03.023_bib55","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/blood.V100.1.334","article-title":"Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide","volume":"100","author":"Eissner","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2017.03.023_bib56","doi-asserted-by":"crossref","first-page":"686","DOI":"10.4161\/cbt.6.5.3959","article-title":"Defibrotide: an endothelium protecting and stabilizing drug, has an anti-angiogenic potential in\u00a0vitro and in\u00a0vivo","volume":"6","author":"Koehl","year":"2007","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ymthe.2017.03.023_bib57","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/MBC.0b013e32832da1e3","article-title":"The fibrinolytic mechanism of defibrotide: effect of defibrotide on plasmin activity","volume":"20","author":"Echart","year":"2009","journal-title":"Blood Coagul, Fibrinolysis."},{"key":"10.1016\/j.ymthe.2017.03.023_bib58","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/107602960100700308","article-title":"Tissue factor pathway inhibitor release induced by defibrotide and heparins","volume":"7","author":"Cella","year":"2001","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"10.1016\/j.ymthe.2017.03.023_bib59","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/BF00609244","article-title":"Acute effects of defibrotide, an experimental antithrombotic agent, on fibrinolysis and blood prostanoids in man","volume":"35","author":"Coccheri","year":"1988","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ymthe.2017.03.023_bib60","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1101\/gad.1941310","article-title":"Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model","volume":"24","author":"Hua","year":"2010","journal-title":"Genes Dev."},{"key":"10.1016\/j.ymthe.2017.03.023_bib61","unstructured":"MDA. Spinal muscular atrophy. http:\/\/www.mda.org\/disease\/spinal-muscular-atrophy\/types."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001617301223?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001617301223?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T12:29:17Z","timestamp":1568982557000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001617301223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":61,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S1525001617301223"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2017.03.023","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FDA-Approved Oligonucleotide Therapies in 2017","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2017.03.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}